Development of a nomogram for predicting survival in clinical T1N0M1 lung adenocarcinoma: a population-based study.
Journal
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837
Informations de publication
Date de publication:
19 Jul 2023
19 Jul 2023
Historique:
medline:
21
7
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
aheadofprint
Résumé
This study aimed to establish a prognostic model for clinical T1N0M1 (cT1N0M1) lung adenocarcinoma patients to evaluate the prognosis of patients in terms of overall survival (OS) rate and cancer-specific survival (CSS) rate. Data of patients with metastatic lung adenocarcinoma from 2010 to 2016 were collected from the Surveillance, Epidemiology and End Results database. Multivariate Cox regression analysis was conducted to identify relevant prognostic factors and used to develop nomograms. The receiver operating characteristic (ROC) curve and calibration curve are used to evaluate the predictive ability of the nomograms. A total of 45610 patients were finally included in this study. The OS and CSS nomograms were constructed by same clinical indicators such as age (<60 years or ≥60 years), sex (female or male), race (white, black, or others), surgery, radiation, chemotherapy, and the number of metastatic sites, based on the results of statistical Cox analysis. From the perspective of OS and CSS, surgery contributed the most to the prognosis. The ROC curve analysis showed that the survival nomograms could accurately predict OS and CSS. According to the points obtained from the nomograms, survival was estimated by the Kaplan-Meier method, then cT1N0M1 patients were divided into three groups: low-risk group, intermediate-risk group, and high-risk group, and the OS (P < 0.001) and CSS (P < 0.001) were significantly different among the three groups. The nomograms and risk stratification model provide a convenient and reliable tool for individualized evaluation and clinical decision-making of patients with cT1N0M1 lung adenocarcinoma.
Identifiants
pubmed: 37477157
doi: 10.1097/CEJ.0000000000000831
pii: 00008469-990000000-00085
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Al-Sarraf N, Aziz R, Gately K, Lucey J, Wilson L, McGovern E, et al. (2008). Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography. Eur J Cardiothorac Surg 33:104–109.
Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, et al.; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions (2015). The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM Classification for Lung Cancer. J Thorac Oncol 10:1675–1684.
Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK (2014). Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 14:535–546.
Collon T, Ba O, Grivaux M, Dore P, Azarian R, Orion B, et al.; CPHG (2004). [Primary non-small-cell lung cancer: analysis of 419 T1 (<or=3 cm) tumors in the KBP-2000-CPHG study]. Rev Pneumol Clin 60:333–343.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. (2017). Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:504–535.
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al.; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions (2016). The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51.
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al.; TRACERx Consortium (2017). Tracking the evolution of non-small-cell lung cancer. N Engl J Med 376:2109–2121.
Kanzaki R, Higashiyama M, Fujiwara A, Tokunaga T, Maeda J, Okami J, et al. (2011). Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study. Lung Cancer 71:333–337.
Lee PC, Port JL, Korst RJ, Liss Y, Meherally DN, Altorki NK (2007). Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg 84:177–181.
Liang W, Zhang L, Jiang G, Wang Q, Liu L, Liu D, et al. (2015). Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J Clin Oncol 33:861–869.
Mitchell KG, Farooqi A, Ludmir EB, Corsini EM, Sepesi B, Gomez DR, et al.; MD Anderson Cancer Center Oligometastatic Lung Cancer Working Group (2021). Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer. J Thorac Cardiovasc Surg 161:1497–1504.e2.
Riihimaki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. (2014). Metastatic sites and survival in lung cancer. Lung Cancer 86:78–84.
Sato T, Shimada Y, Mimae T, Tsutani Y, Miyata Y, Ito H, et al. (2021). The impact of pathological lymph node metastasis with lymphatic invasion on the survival of patients with clinically node-negative non-small cell lung cancer: a multicenter study. Lung Cancer 158:9–14.
Seok Y, Yang HC, Kim TJ, Lee KW, Kim K, Jheon S, et al. (2014). Frequency of lymph node metastasis according to the size of tumors in resected pulmonary adenocarcinoma with a size of 30 mm or smaller. J Thorac Oncol 9:818–824.
Shan Q, Fan Y, Guo J, Han X, Wang H, Wang Z (2019). Relationship between tumor size and metastatic site in patients with stage IV non-small cell lung cancer: a large SEER-based study. PeerJ 7:e7822.
Shi J, Hua X, Zhu B, Ravichandran S, Wang M, Nguyen C, et al. (2016). Somatic genomics and clinical features of lung adenocarcinoma: a retrospective study. PLoS Med 13:e1002162.
Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, Aquilanti E, et al. (2020). Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet 52:371–377.
Wang Z, Gao SG, Xue Q, Guo XT, Wang LX, Yu X, et al. (2018). Surgery of primary non-small cell lung cancer with oligometastasis: analysis of 172 cases. J Thorac Dis 10:6540–6546.
Xu J, Fan L, Yu H, Lu D, Peng W, Sun G (2020). Survival value of primary tumour resection for stage IV non-small-cell lung cancer: a population-based study of 6466 patients. Clin Respir J 14:763–771.
Yin G, Xiao H, Liao Y, Huang C, Fan X (2020). Construction of a nomogram after using propensity score matching to reveal the prognostic benefit of tumor resection of stage IV M1a nonsmall cell lung cancer patients. Cancer Invest 38:277–288.
Zhang YK, Chai ZD, Tan LL, Wang ZY, Chen ZJ, Le HB, et al. (2017). Association of lymph node involvement with the prognosis of pathological T1 invasive non-small cell lung cancer. World J Surg Oncol 15:64.
Zhu T, Bao X, Chen M, Lin R, Zhuyan J, Zhen T, et al. (2020). Mechanisms and future of non-small cell lung cancer metastasis. Front Oncol 10:585284.
Zuo Z, Zhang G, Song P, Yang J, Li S, Zhong Z, et al. (2021). Survival nomogram for stage IB Non-small-cell lung cancer patients, based on the SEER database and an external validation cohort. Ann Surg Oncol 28:3941–3950.